SUMMARY This review suggests that immunocytochemistry in diagnostic pathology can be performed using relatively small panels of antibodies and that it should be reserved for situations in which, for one reason or another, the pathologist cannot exert his or her conventional diagnostic skills. Examples include the diagnosis of tumours the true nature of which is uncertain because of anaplasia or poor morphological preservation; the demonstration of small numbers of cells which are otherwise too rare to be recognised in conventionally stained preparations; and the immunophenotyping of non-Hodgkin's lymphomas. Recently progress has been made in the context of non-Hodgkin's lymphomas by the development of monoclonal antibodies that detect T and B cell associated markers in paraffin wax sections. Most of these reagents, however, recognise either lineage associated (but not lineage specific) variants of the leucocyte common antigen CD45, or antigens that are poorly characterised. A recent promising development has therefore been the demonstration that polyclonal antisera raised against the CD3/T3 T cell specific marker (purified by affinity chromatography) are suitable for staining T cells in paraffin sections. This approach will hopefully enable antibodies to be produced which react with other well defined white cell associated markers in routine biopsy material.
This issue of the Journal of Clinical Pathology celebrates the foundation 25 years ago of the Royal College of Pathologists. Immunocytochemistry as a major technique in diagnostic pathology cannot claim to be of comparable antiquity: although immunocytochemical methods were used diagnostically in a number of laboratories in the 1 960s for purposes such as the demonstration of autoantibodies, they did not become of practical relevance to the general histopathologist until the early 1970s. The present review traces the development since that time of immunocytochemistry as a diagnostic procedure in pathology, and considers how these methods may become of even wider scope in the future.
Early studies
Pathologists first became aware of the extent to which immunocytochemistry might be applied in diagnostic histopathology in 1974 after the publication by Taylor and Burns in the Journal of Clinical Pathology, which reported that immunoperoxidase labelling could show the presence of plasma cell immunoglobulin in paraffin embedded tissues.' In retrospect, this may seem a minor technical discovery, but at the time it was widely accepted that routinely processed paraffin embedded tissue was quite unsuitable for immunocytochemical analysis. For the first time histopathologists were offered the exciting possibility of being able not only to widen the scope of their diagnostic procedures, but also to study retrospectively tissue which had been stored for many years.
The feasibility of detecting immunoglobulin in routinely processed paraffin embedded tissue was soon confirmed by other laboratories,2 3 although the hope that it would provide a simple and reliable means of immunophenotyping lymphomas in the diagnostic histopathology laboratory proved premature. Indeed, in retrospect, it is unfortunate that immunoglobulins, and in particular K and A light chains, were the first antigens to be detected in routinely processed tissue, as they are present in such high amounts in the circulation that cellular staining for immunoglobulin is as likely to represent diffusion artefacts as endogenous synthesis. 4 6 The median way may be found by keeping in mind that immunocytochemistry is most valuable in pathology when the normal means by which the pathologist exerts his or her diagnostic skills are thwarted for some reason. At this point immunocytochemistry comes into its own and can play an invaluable part in achieving a final diagnosis. Conversely, the clearer a diagnosis is after conventional morphological examination, the less likely it is that immunocytochemistry will have a role. Indeed, immunocytochemical investigations of samples in which the diagnosis is not in dispute are positively to be discouraged; at best they may confirm what is already known and at worst they are at odds with the diagnosis, causing ridicule and loss of face.
Guided by this rule one can identify the specific instances in which immunocytochemistry has a practical part to play. These are summarised in table 3.
DIAGNOSIS OF THE TUMOUR OF UNCERTAIN ORIGIN
One of the great successes in the application of immunocytochemistry to diagnostic pathology lies in the resolution of problems relating to the diagnosis of tumours of uncertain origin.'920 Such diagnostic 1044 Mason, Gatter Initflusiot)ltoclhePnii.strvl in (liaignostic pathology difficulty sometimes arises because cellular morphology, although well preserved, is uninformative. In other cases the tissue sample shows such severe distortion, either through physical damage for example, crushing during biopsy-or from poor fixation that normal morphological criteria can no longer be applied with confidence ( fig 3) . In both these instances immunocytochemical labelling is often very informative. A simple flow chart which summarises the patterns that enable different tumour cell types to be distinguished is given in fig 4 Mason, Gatter ing its relation to CD45R antibodies, and it may show minor differences in reactivity from other members of the group.
One of the anti-T cell antibodies from Poppema's laboratory (MTl) may also have had an equivalent among the third workshop antibodies since antibody UCHL1 from Beverley's laboratory30 recognises only the smallest 180 kD polypeptide and reacts with most T cells (possibly selectively with memory T cells) and with some histiocytes/macrophages. Its immunocytochemical reactions are therefore similar to those of antibody MTl, although, as in the case of antibody MBI and CD45R reagents, on the basis of existing evidence it cannot be concluded that the antibodies are of identical specificity. UCHL1 has been used extensively by Isaacson's group in the diagnosis of lymphoproliferative disorders and seems to be a good marker for T cell neoplasms. 31 In addition to the MT and MB series of antibodies, two antibodies (designated LN-1 and LN-2), which react with B cell antigens in paraffin sections, have been reported by Epstein et al. 32 Their reactions (and those of a third reagent LN-3 which recognises HLA-DR) on lymphoid neoplasms were documented in a paper from the same laboratory (table 5).33  Table 6 provides a comparative summary of the monoclonal antibodies discussed above and attempts to relate them to each other in terms of probable specificity. Fig 6 shows an example of the use of antibodies against T cell and B cell associated variants of the leucocyte common antigen for immunophenotyping a paraffin embedded lymphoma biopsy specimen.
ANTI-HLA-DR ANTIBODIES
Epenetos et al reported that antibody TAL-IB5, raised against purified HLA-DR a chain, will detect HLA-DR antigen in paraffin embedded tissue.34 Antibody LN-3, reported by Marder et al (table 5) , and also an antibody (CR3/43) from our own laboratory, seem to behave in the same way. The broad distribution of HLA-DR limits their use as markers of neoplastic white cells to some extent; although the fact that B cell neoplasms are almost always HLA-DR positive, and T cell lymphomas only occasionally so, may be of value in the context of lymphoma phenotyping.
ANTI-HAPTEN x (CD15) ANTIBODIES
Many laboratories have raised monoclonal antibodies against this oligosaccharide grouping (which seems to be particularly immunogenic in the mouse).15 -7 Initially thought of principally as a marker for granulocytes, the antigen was subsequently shown to be present in Reed-Sternberg and Hodgkin's cells.35 36 It appears, however, not to be 
Conclusions
From the preceding discussion it is apparent that there is still great scope for the production of monoclonal antibodies which will work reliably on paraffin embedded tissue sections. Most of the antibodies discussed above that are suitable for use in this way suffer from one or more of the following shortcomings: (1) they are directed against molecules which are poorly defined or even uncharacterised in terms of molecular weight; (2) the molecules they detect are only associated with T or B cells and are not truly specific for one of these cell lineages; (3) they are produced by a unique hybridoma and are hence often not widely distributed for comparative studies.
One step towards overcoming these limitations will come from directing attention to those antigens defined by the CD system that are essentially specific for T or B cells. Antigens CD l-CD8 and CD27 constitute well characterised and relatively specific markers for T cells or their subpopulations, while for B cells CD19-CD23 and CD37 would be appropriate for further study in this context. New and existing A promising field of endeavour may therefore lie in the raising of monoclonal antibodies against purified CD antigens. Many white cell antigens can now be isolated relatively easily using appropriate monoclonal antibody affinity columns, and it is even possible that the very process of purification will cause denaturation of the molecules and hence the induction of epitopes present only in paraffin embedded tissue. Preliminary immunocytochemical studies in collaboration with Dr M Crumpton's laboratory suggest the feasibility of this approach (fig 8) as a polyclonal antiserum against purified T3 (CD3) antigen (prepared by Dr G Krissansen) gives excellent staining of normal and neoplastic T cells in paraffin embedded tissue (Mason DY , Krissansen GW, Davey FR, et al, unpublished observations). The fact that this work was performed using a polyclonal antiserum, however, clearly limits its wider application, and it will be of great interest to see whether, in the next few years, the strategy of immunisation with purified CD3 antigen will lead to the production of monoclonal reagents which duplicate the reactivity of this antiserum. Hopefully the same approach may also yield monoclonal antibodies capable of detecting other well characterised T and B cell associated molecules in paraffin sections.
Paraffin wax embedded tissue from one of Thomas Hodgkin's original cases was kindly provided by Dr R Poston.
